TY - JOUR
T1 - Statistical analysis of maxillary sinus squamous cell carcinoma
AU - Yamashita, Taku
AU - Fujii, Masato
AU - Ishiguro, Ryuichirou
AU - Tashiro, Masatsugu
AU - Ohno, Yoshihiro
AU - Tokumaru, Yutaka
AU - Kanke, Minoru
AU - Imanishi, Yorihisa
AU - Tomita, Toshiki
AU - Kanzaki, Jin
AU - Inuyama, Yukio
PY - 2002
Y1 - 2002
N2 - Cases of squamous cell carcinoma of the maxillary sinus initially treated at Keio University Hospital between January 1981 and December 1998 studied retrospectively involved 60 untreated cases - 46 men and 14 women aged 36 to 86 years (mean: 59.8 years). Of these, 7 had T2, 41 T3 and 12 T4 tumors based on 1997 AJCC TNM classification. Seven (11.7%) had nodal involvement but none had distant metastasis at diagnosis. Of the 60, 53 (88.3%) were stage III or IV. Prognostic factors and survival were statistically analyzed for 59 cases, excluding the 60th who died of another cause. Follow-up was 4 to 227 months, with a median of 59 months and a mean of 38 months. Of the 59, 48 (81.4%) underwent neoadjuvant chemotherapy (NAC). Survival was estimated using the Kaplan-Meier method as univariate analysis. Cause-specific 5-year survival was 56.8% for all stages, 68.2% for T2, 60.0% for T3, and 41.7% for T4. T stage classification was thus a significant independent prognostic factor in multivariate analysis using Cox's proportional hazards model (p= 0.0240). It also identified T stage classification (p=00486) and NAC (p=0.0419) as significant independent factors affecting survival with organ preservation. We also statistically analyzed 48 cases treated with NAC, which showed complete response (CR) for 11, partial response (PR) for 25. no change (NC) for 11, and progressive disease (PD) for 1. Responders (CR+PR) showed significantly better survival and organ preservation than nonresponders (NC+PD). The NAC response enables us to predict prognosis. T4 cases without NAC response should be treated intensively.
AB - Cases of squamous cell carcinoma of the maxillary sinus initially treated at Keio University Hospital between January 1981 and December 1998 studied retrospectively involved 60 untreated cases - 46 men and 14 women aged 36 to 86 years (mean: 59.8 years). Of these, 7 had T2, 41 T3 and 12 T4 tumors based on 1997 AJCC TNM classification. Seven (11.7%) had nodal involvement but none had distant metastasis at diagnosis. Of the 60, 53 (88.3%) were stage III or IV. Prognostic factors and survival were statistically analyzed for 59 cases, excluding the 60th who died of another cause. Follow-up was 4 to 227 months, with a median of 59 months and a mean of 38 months. Of the 59, 48 (81.4%) underwent neoadjuvant chemotherapy (NAC). Survival was estimated using the Kaplan-Meier method as univariate analysis. Cause-specific 5-year survival was 56.8% for all stages, 68.2% for T2, 60.0% for T3, and 41.7% for T4. T stage classification was thus a significant independent prognostic factor in multivariate analysis using Cox's proportional hazards model (p= 0.0240). It also identified T stage classification (p=00486) and NAC (p=0.0419) as significant independent factors affecting survival with organ preservation. We also statistically analyzed 48 cases treated with NAC, which showed complete response (CR) for 11, partial response (PR) for 25. no change (NC) for 11, and progressive disease (PD) for 1. Responders (CR+PR) showed significantly better survival and organ preservation than nonresponders (NC+PD). The NAC response enables us to predict prognosis. T4 cases without NAC response should be treated intensively.
KW - Maxillary sinus carcinoma
KW - Multivariate analysis
KW - Neoadjuvant chemotherapy
KW - Prognostic factor
UR - http://www.scopus.com/inward/record.url?scp=11244249513&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=11244249513&partnerID=8YFLogxK
U2 - 10.3950/jibiinkoka.105.732
DO - 10.3950/jibiinkoka.105.732
M3 - Article
C2 - 12138701
AN - SCOPUS:11244249513
SN - 0030-6622
VL - 105
SP - 732
EP - 740
JO - Journal of Otolaryngology of Japan
JF - Journal of Otolaryngology of Japan
IS - 6
ER -